Voyager Therapeutics Inc (NASDAQ:VYGR) major shareholder Neurocrine Biosciences Inc purchased 4,179,728 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were acquired at an average cost of $11.96 per share, for a total transaction of $49,989,546.88. Following the transaction, the insider now owns 4,179,728 shares of the company’s stock, valued at $49,989,546.88. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Voyager Therapeutics stock opened at $19.66 on Friday. Voyager Therapeutics Inc has a 52-week low of $7.76 and a 52-week high of $24.24. The company has a market capitalization of $641.25 million, a P/E ratio of -7.15 and a beta of 2.77.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, February 26th. The company reported ($0.70) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.70). Voyager Therapeutics had a negative return on equity of 120.82% and a negative net margin of 1,158.79%. Equities analysts expect that Voyager Therapeutics Inc will post -2.93 earnings per share for the current year.

VYGR has been the topic of a number of research analyst reports. Zacks Investment Research raised Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Saturday, November 17th. HC Wainwright set a $25.00 price target on Voyager Therapeutics and gave the stock a “buy” rating in a research report on Friday, November 30th. BTIG Research dropped their price target on Voyager Therapeutics to $23.00 and set a “positive” rating on the stock in a research report on Tuesday, January 8th. Chardan Capital reaffirmed a “neutral” rating on shares of Voyager Therapeutics in a research report on Thursday, January 10th. Finally, ValuEngine lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $24.00.

Institutional investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY raised its position in Voyager Therapeutics by 449.4% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after buying an additional 7,401 shares during the last quarter. Bank of America Corp DE grew its stake in Voyager Therapeutics by 211.0% in the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after purchasing an additional 7,217 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in Voyager Therapeutics by 66.8% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after purchasing an additional 4,559 shares in the last quarter. AlphaCrest Capital Management LLC bought a new position in Voyager Therapeutics in the fourth quarter valued at approximately $102,000. Finally, Weiss Multi Strategy Advisers LLC grew its stake in Voyager Therapeutics by 10.0% in the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 11,000 shares of the company’s stock valued at $103,000 after purchasing an additional 1,000 shares in the last quarter. 85.37% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences Inc Purchases 4,179,728 Shares of Voyager Therapeutics Inc (VYGR) Stock” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/neurocrine-biosciences-inc-purchases-4179728-shares-of-voyager-therapeutics-inc-vygr-stock/2896164.html.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Recommended Story: Options Trading – What is a Straddle?

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.